Patents by Inventor Johanna GELLERT

Johanna GELLERT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-MUC1 antibody-drug conjugate
    Patent number: 11872289
    Abstract: The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.
    Type: Grant
    Filed: August 1, 2022
    Date of Patent: January 16, 2024
    Assignee: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna Gellert, Anke Flechner, Doreen Weigelt, Antje Danielczyk, Akiko Nagase
  • ANTI-MUC1 ANTIBODY-DRUG CONJUGATE
    Publication number: 20230372520
    Abstract: The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.
    Type: Application
    Filed: July 10, 2023
    Publication date: November 23, 2023
    Applicant: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna GELLERT, Anke FLECHNER, Doreen WEIGELT, Antje DANIELCZYK, Akiko NAGASE
  • HUMANIZED ANTIBODIES AGAINST LEWIS Y
    Publication number: 20230235076
    Abstract: The present invention pertains to humanized anti-Lewis Y antibodies which specifically bind to Lewis Y and do not show any cross-reactivity. Especially, the humanized anti-Lewis Y antibodies do not bind to Lewis b or any other blood group carbohydrate antigen. In particular, the present invention is directed to humanized anti-Lewis Y antibodies which are useful in the treatment of cancer.
    Type: Application
    Filed: June 29, 2021
    Publication date: July 27, 2023
    Inventors: Antje DANIELCZYK, Johanna GELLERT, Anke FLECHNER, Patrik KEHLER
  • ANTI-MUC1 ANTIBODY-DRUG CONJUGATE
    Publication number: 20230139769
    Abstract: The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.
    Type: Application
    Filed: August 1, 2022
    Publication date: May 4, 2023
    Applicant: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna GELLERT, Anke FLECHNER, Doreen WEIGELT, Antje DANIELCZYK, Akiko NAGASE
  • ANTI-MUC1 ANTIBODY
    Publication number: 20210221910
    Abstract: The present disclosure pertains to novel antibodies directed against the cancer antigen MUC1. In particular, an antibody with improved antigen binding was obtained by deleting a glycosylation site in the CDR-H2 of a known anti-MUC1 antibody.
    Type: Application
    Filed: May 17, 2019
    Publication date: July 22, 2021
    Applicant: GLYCOTOPE GMBH
    Inventors: Johanna GELLERT, Anke FLECHNER, Doreen WEIGELT, Antje DANIELCZYK
  • ANTI-MUC1 ANTIBODY-DRUG CONJUGATE
    Publication number: 20210187118
    Abstract: The present disclosure relates to antibody drug conjugates directed against the cancer antigen MUC1. In particular, an antibody with improved antigen binding was obtained by deleting a glycosylation site in the CDR-H2 of a known anti-MUC1 antibody. The conjugates consist of exatecan derivatives coupled to the anti MUC1 antibodies.
    Type: Application
    Filed: May 17, 2019
    Publication date: June 24, 2021
    Applicant: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna GELLERT, Anke FLECHNER, Doreen WEIGELT, Antje DANIELCZYK, Akiko NAGASE
  • Fusion Protein Constructs Comprising an Anti-MUC1 Antibody and IL-15
    Publication number: 20210107961
    Abstract: The present invention pertains to fusion protein constructs comprising an antibody against the cancer antigen MUC1 and IL-15. In particular, the fusion protein constructs activate NK cells and T cells at the cancer site.
    Type: Application
    Filed: March 1, 2019
    Publication date: April 15, 2021
    Inventors: Johanna GELLERT, Patrik KEHLER, Anika JÄKEL, Laura DIX, Antje DANIELCZYK, Steffen GOLETZ
  • MULTISPECIFIC ANTIBODY CONSTRUCTS BINDING TO MUC1 AND CD3
    Publication number: 20200131275
    Abstract: The present invention pertains to multispecific antibody constructs directed against the cancer antigen MUC1 and the T cells antigen CD3. In particular, the multispecific antibody constructs recruit T cells to the cancer site. The design of the multispecific antibody constructs show strong antigen binding and high T cell activation.
    Type: Application
    Filed: March 27, 2018
    Publication date: April 30, 2020
    Inventors: Steffen GOLETZ, Patrik KEHLER, Johanna GELLERT, Antje DANIELCZYK, Anika JÄKEL